Stockreport

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics, Inc.  (IPSC) 
PDF - Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - [Read more]